Conv. Plasma
Nigella Sativa
Peg.. Lambda

All cannabidiol studies
Meta analysis
Home COVID-19 treatment researchCannabidiolCannabidiol (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -181% Improvement Relative Risk Case 19% Cannabidiol for COVID-19  Huang et al.  Prophylaxis Is prophylaxis with cannabidiol beneficial for COVID-19? Retrospective 13,099 patients in the United Kingdom Higher mortality (p=0.041) and fewer cases (p=0.0001) Huang et al., Frontiers in Public Health, Mar 2022 Favors cannabidiol Favors control

Cannabis use is associated with lower COVID-19 susceptibility but poorer survival

Huang et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.829715
Mar 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
UK Biobank retrospective with 13,099 cannabis users, showing a lower risk of COVID-19 infection, however regular users had a significantly higher risk of mortality.
risk of death, 181.0% higher, HR 2.81, p = 0.04, regular users, Cox proportional hazards.
risk of case, 19.0% lower, OR 0.81, p < 0.001, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 8 Mar 2022, retrospective, United Kingdom, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Cannabis Use Is Associated With Lower COVID-19 Susceptibility but Poorer Survival
Da Huang, Roubing Xu, Rong Na
Frontiers in Public Health, doi:10.3389/fpubh.2022.829715
Objectives: To investigate the impact of cannabis use on the infection and survival outcomes of COVID-19. Study Design: Cross-sectional study based on the UK Biobank (UKB) dataset. Methods: We identified 13,099 individuals with cannabis smoking history in the UKB COVID-19 Serology Study. The Charlson-Quan Comorbidity Index was estimated using inpatient ICD-10 records. Multivariable logistic regression characterized features associated with COVID-19 infection. Cox models determined the hazard ratios (HR) for COVID-19-related survival. Results: Cannabis users were more likely to getting COVID-19 (odds ratio: 1.22, P = 0.001) but multivariable analysis showed that cannabis use was a protective factor of COVID-19 infection (adjusted odds ratio: 0.81, P = 0.001). Regular cannabis users, who smoked more than once per month, had a significantly poorer COVID-19-related survival, after adjusting for known risk factors including age, gender, smoking history, and comorbidity (adjusted hazard ratio: 2.81, P = 0.041). Conclusions: The frequency of cannabis use could be considered as a candidate predictor for mortality risk of COVID-19.
AUTHOR CONTRIBUTIONS RN conceived and designed the study. DH, RX, and RN extracted and analyzed the data. DH and RN wrote the manuscript. All authors contributed to the article and approved the final version. Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Cousijn, Kuhns, Larsen, Kroon, For better or for worse? A pre-post exploration of the impact of the COVID-19 lockdown on cannabis users, Addiction, doi:10.1111/add.15387
Csete, Kamarulzaman, Kazatchkine, Altice, Balicki et al., Public health and international drug policy, Lancet, doi:10.1016/S0140-6736(16)00619-X
Davies, Klepac, Liu, Prem, Jit et al., Agedependent effects in the transmission and control of COVID-19 epidemics, Nat Med, doi:10.1038/s41591-020-0962-9
Fry, Littlejohns, Sudlow, Doherty, Adamska et al., Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population, Am J Epidemiol, doi:10.1093/aje/kwx246
Imtiaz, Wells, Rehm, Hamilton, Nigatu et al., Cannabis use during the COVID-19 pandemic in Canada: a repeated cross-sectional study, J Addict Med, doi:10.1097/ADM.0000000000000798
Li, Zheng, Ulsa, Yang, Scheer et al., Poor sleep behavior burden and risk of COVID-19 mortality and hospitalization, Sleep, doi:10.1093/sleep/zsab138
Quan, Sundararajan, Halfon, Fong, Burnand et al., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Med Care, doi:10.1097/01.mlr.0000182534.19832.83
Sudlow, Gallacher, Allen, Beral, Burton et al., UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age, PLoS Med, doi:10.1371/journal.pmed.1001779
Verity, Okell, Dorigatti, Winskill, Whittaker et al., Estimates of the severity of coronavirus disease 2019: a model-based analysis, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30243-7
Volkow, Baler, Compton, Weiss, Adverse health effects of marijuana use, N Engl J Med, doi:10.1056/nejmra1402309
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop